PHILLIPSBURG, N.J.--(BUSINESS WIRE)--May 5, 2005--Sentigen Holding Corp. (NasdaqSC: SGHL), today reported results for the first quarter ended March 31, 2005. On February 22, 2005 we sold the Specialty Media Division of our wholly-owned subsidiary, Cell & Molecular Technologies, Inc. (“CMT”) to Chemicon International, Inc., a wholly-owned subsidiary of Serologicals Corporation (Nasdaq: SERO). As such the results of this division have been accounted for as discontinued operations. Our consolidated results of continuing operations consist of CMT’s contract research division, Sentigen Biosciences, Inc. and the expenses of the parent company.
